/

Empresas

Ge

No verificado

Genethon

Sobre qué escribimos

BiotecnologíaCienciaFarmacéuticaMedicina - VariosSalud

17 Comunicados de prensa

Ver todos los comunicados de prensa

13/07/2026

Industria

Salud

Biotecnología

Medicina - Varios

Ciencia

Farmacéutica

Genethon’s Recent Accomplishments Underscore the Progress of Genetic Medicine from Scientific Promise to Clinical Reality

Fuente

Editor

1.00

0

11/03/2026

Eventos

Salud

Ciencia

Farmacéutica

Medicina - Varios

Gene Therapy for Duchenne Muscular Dystrophy: Genethon Confirms Two-Year Efficacy in Patients Treated with Its Drug Candidate GNT0004 at Therapeutic Dose in the First Phase of Its Clinical Trial

Fuente

Editor

1.00

0

26/01/2026

Ciencia

Infancia

Biotecnología

Medicina - Varios

Salud

Ir de compras

Farmacéutica

Mercado laboral

Industria

Genethon Advances Groundbreaking Gene Therapies for Patients with Rare Genetic Diseases

Fuente

Editor

1.00

0

14/01/2026

Voluntariado/Solidaridad/ONGs

Mercado laboral

Ciencia

Biotecnología

Farmacéutica

Sanidad

Salud

Medicina - Varios

Genethon Signs Licensing Agreement With AskBio for the Development of an Investigational Gene Therapy for Pompe Disease

Fuente

Editor

1.00

0

06/01/2026

Eventos

Web y redes sociales

Ciencia

Biotecnología

Farmacéutica

Sanidad

Salud

Medicina - Varios

Genethon Management to Host Partnering Meetings During JP Morgan Healthcare Week, January 12 -16, 2026 in San Francisco, CA

Fuente

Editor

1.00

0

10/10/2025

Multimedia

Ciencia

Biotecnología

Farmacéutica

Sanidad

Salud

Medicina - Varios

Eventos

Ferias y Congresos

Industria

Data from GNT-018-IDES Trial Supports Feasibility of imlifidase as Pretreatment in Gene Therapy Treatment for Patients With Crigler–Najjar Syndrome Who Are Immune to AAV

Fuente

Editor

1.00

0

09/10/2025

Ciencia

Biotecnología

Farmacéutica

Sanidad

Salud

Medicina - Varios

Web y redes sociales

Voluntariado/Solidaridad/ONGs

Eventos

Industria

Genethon Confirms 2-Year Efficacy in Duchenne Muscular Dystrophy Patients Treated With Its Low Dose Micro-Dystrophin Gene Therapy (GNT0004) at the ESGCT 32nd Annual Congress

Fuente

Editor

1.00

0

28/07/2025

Industria

Biotecnología

Salud

Farmacéutica

Medicina - Varios

Genethon to Launch Pivotal Trial in Europe of GNT0004 a Low-Dose Microdystrophin Gene Therapy for Duchenne Muscular Dystrophy

Fuente

Editor

1.00

0

19/06/2025

Biotecnología

Salud

Farmacéutica

Medicina - Varios

Eventos

Clinical Milestones, Vector Innovation Key to Gene Therapy, GenoTher Biocluster’s First International Summit, Atamyo Therapeutics’ Progress for LGMDs Highlight Genethon’s Most Recent Newsletter

Fuente

Editor

1.00

0

19/05/2025

Eventos

Biotecnología

Salud

Farmacéutica

Medicina - Varios

Genethon Presents Two Year Consolidated Results of Its Gene Therapy Trial for Duchenne Muscular Dystrophy: Maintenance of Motor Functions and Significant, Sustained Reduction in CPK Levels in Patients Treated at the Effective Dose at ASGCT 2025

Fuente

Editor

1.00

0

Seguidores

0

Compatibilidad

0